Imunon (NASDAQ:IMNN) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Imunon (NASDAQ:IMNN) in a research report report published on Thursday morning,Benzinga reports. D. Boral Capital currently has a $29.00 price objective on the stock.

Several other analysts also recently weighed in on IMNN. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Imunon in a research note on Wednesday, December 11th. EF Hutton Acquisition Co. I raised Imunon to a “strong-buy” rating in a research report on Monday, September 23rd.

Imunon Price Performance

IMNN stock opened at $0.83 on Thursday. Imunon has a 12 month low of $0.48 and a 12 month high of $3.65. The firm’s 50-day moving average is $0.87 and its 200 day moving average is $1.07. The company has a market capitalization of $12.04 million, a PE ratio of -0.44 and a beta of 2.12.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.